QPS buys majority stake in Qualitix

- Last updated on GMT

QPS has bought a majority interest in Qualitix Clinical Research to bolster its clinical trial management services offering.

Qualitix, which will operates as Qualitx-QPS, provides phase I-VI trial management and regulatory services, has offices in Taiwan and China and was spun out from Genovate, which still maintains a minority interest.

The firm also runs a dedicated site management organisation, Unitix, which is focused on accelerating patient recruitment.

QPS said that: “With its strong Asia-Pacific regional network of CRO partners, QPS-Qualitix acts as an attractive launching point from which clients may address the rapidly growing Asian market.”

Vincent​Yen, CEO of QPS-Taiwan. "This represents the fourth cross-border acquisition QPS has made in the last six months. Clients all over the world will now have access to an even wider range of the exceptional services they have come to expect from QPS, along with an expanding global footprint​."

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers